

VIRTUO and 802(15.6%) for BACTEC (p=0.0003). TTD and proportion of aerobic/anaerobic bottles is shown in Table.

Hands-on-time was reduced by 15 minutes/day when using VIRTUO.

Table

Conclusion. We have compared on a large scale and in a “real world” setting the performance of two automatic blood culture incubators. TTD was significantly lower for the VIRTUO incubated samples, with differences in both systems depending on the type of bottle (aerobic vs. anaerobic). The number of positive results was significantly higher for the VIRTUO incubated samples, which might impact antimicrobial prescription and clinical outcomes.

		VIRTUO	BACTEC	P value (Log Rank Test)
TTD (hours)				
All Positive	All bottles	15.2	16.7	<0.0001
	Aerobic	15.2	19.1	<0.0001
	Anaerobic	15.3	12.7	0.7867
Contaminants	All bottles	19.1	22.2	<0.0001
	Aerobic	17.1	21.4	<0.0001
	Anaerobic	25.5	25.3	0.0410
Significant Organisms	All bottles	11.0	11.9	0.0014
	Aerobic	11.8	15.3	<0.0001
	Anaerobic	1.2	11.0	0.9712

Disclosures. Ana V. Halperin, MD, Biomérieux (Grant/Research Support) José Luis Cortés Cuevas, MD, biomérieux (Research Grant or Support) biomérieux (Research Grant or Support) Juan Antonio Del Castillo Polo, MD, Biomérieux (Research Grant or Support) Sergio Talens, n/a, Biomérieux (Research Grant or Support) Robert Birch, n/a, bioMérieux Inc. (Employee) Rafael Cantón, PharmD PhD, Biomérieux (Grant/Research Support)

12. Evaluation of Rapid Phenotypic Testing for KPC Carbapenemase Producing *Klebsiella pneumoniae* Directly from Positive Blood Cultures by Use of “Hot Chocolate” Plates

Alexander Lawandi, M.D.¹; Gleice C. Leite, PhD²; Brigitte Lefebvre, PhD³; Jean Longtin, MD⁴; Todd C. Lee, MD, MPH⁵; ¹Division of Infectious Diseases, McGill University Health Centre, McGill University, Montreal, Canada, Montreal, Quebec, Canada; ²McGill University Health Centre, Montréal, Quebec, Canada; ³Institut National de Santé Publique du Québec, Montreal, Quebec, Canada; ⁴Université Laval, Montréal, Quebec, Canada; ⁵McGill University, Montreal, Quebec, Canada

Session: O-3. Advances in Time to Test Results in the Bacteriology Lab

Background. Invasive infections with Carbapenemase Producing *Enterobacterales* are associated with considerable morbidity and mortality, in part due to the risk of inappropriate empiric therapy. Consequently, the rapid identification of carbapenem resistance is crucial to the management of these infections. We sought to evaluate possible reductions in turnaround time to identification of this resistance in blood cultures growing these organisms by applying rapid phenotypic test kits to growth from “hot chocolate” plates.

Methods. 30 blood cultures, spiked with carbapenem resistant *Klebsiella pneumoniae* isolates or susceptible controls, were inoculated onto chocolate agars that had pre-warmed at 37°C. These plates were incubated at 37°C for 3.5 hours. The resulting minimal growth was then identified using MALDI-TOF and underwent rapid phenotypic testing using three commercially available products (β-lacta and β-carba, from Bio-Rad, Marnes-la-Coquette, France, and Carba-NP, from bioMérieux, Durham, NC). The time to identification of carbapenem resistance using this method was then compared to that of the conventional laboratory workup.

Results. The identification was 100% accurate to the species level using MALDI-TOF paired to the 3.5 hour growth on the “hot chocolate” plates. The β-lacta kit identified resistance to 3rd generation cephalosporins for all ESBL and carbapenemase producing *Klebsiella pneumoniae* isolates, while the β-carba and Carba-NP kits identified carbapenem resistance only in the carbapenemase producers. The sensitivity of all assays was 100% (95% CI 0.87–1.0) and the specificity of carbapenemase detection was 100% (97.5% one-sided CI 0.4–1.0). The corresponding sensitivities and specificities of direct disc diffusion for ertapenem resistance detection were 88.5% (95% CI 0.70–0.98) and 100% (95% CI 0.40–1.0) respectively. The turnaround time for the rapid kits coupled to the “hot chocolate” plates was 4.25 to 5.1 hours as compared to 16 hours for the conventional workup.

Conclusion. Rapid phenotypic tests performed after inoculation of “hot chocolate” plates are highly sensitive for the presence of carbapenemase production and can be incorporated into the laboratory workflow for *Klebsiella pneumoniae* with important reductions in turnaround time.

Disclosures. All Authors: No reported disclosures

13. Evaluation of Etest for Antibiotic Susceptibility and Minimum Inhibitory Concentration (MIC) Agreement Against *Pseudomonas aeruginosa* (psa) from Patients with Cystic Fibrosis (CF)

Maxwell J. Lasko, PharmD¹; Holly Huse, PhD, D(ABMM)²; Joseph L. Kuti, PharmD³; David P. Nicolau, PharmD⁴; ¹Center for Anti Infective Research and Development, Hartford, Connecticut; ²Huntington Hospital, Pasadena, California; ³Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut; ⁴Hartford Hospital, Hartford, Connecticut

Session: O-3. Advances in Time to Test Results in the Bacteriology Lab

Background. CF acute pulmonary exacerbations are often caused by PSA, including multi-drug resistant strains. Optimal antibiotic therapy is required to return lung

function and should be guided by *in vitro* susceptibility results. There are sparse data on the performance of Etest relative to reference broth microdilution (BMD) for many newer drugs against CF PSA. Herein, we describe Etest performance with 10 anti-PSA antibiotics against CF isolates.

Methods. Contemporary, clinical PSA (n=105) isolated during pulmonary exacerbation from patients with CF were acquired from 3 US hospitals. MICs were assessed by BMD (reference) and Etest for aztreonam (ATM), cefepime (FEP), ceftazidime (CAZ), ceftazidime/avibactam (CZA), ceftolozane/tazobactam (C/T), ciprofloxacin (CIP), levofloxacin (LVX), meropenem (MEM), piperacillin/tazobactam (TZP), and tobramycin (TOB). Each respective MIC was completed in at least triplicate using the same inoculum between methods. Modal MICs for each method were compared by rates of essential agreement (EA), categorical agreement (CA), minor error (miE), major error (ME), and very major error (VME) rates. All miE, ME and VME were adjusted if within EA.

Results. Of the 105 PSA, 46% had a mucoid phenotype. Results are summarized in the Table. Median modal Etest MICs read 0–1 dilution higher (IQR: 0–1) than BMD. CA and EA ranged from 64–93% and 63–86%, respectively. Single VMEs occurred for ATM (2.9%) and CAZ (4.2%). For CZA, 2 VMEs were observed and both were within EA. Major errors were ≤3% except for ATM (3.3%), MEM (3.3%), CZA (5.3% with adjusted ME 2.1%), and FEP (13%). Minor error rates were <10% except for TZP, CIP, LEV, TOB, and FEP (13–29%), for which majority of miE were within EA (3/14, 11/16, 10/18, 13/19, 20/31, respectively). Performance was similar for non-mucoid and mucoid populations.

Etest Performance

Conclusion. Etest methods performed well for most antibiotics against this challenging collection of PSA from CF patients. Laboratories should be cautious of miE and ME that may occur with certain antibiotics. Furthermore, our observations suggest laboratories confirm CZA results for isolates with MICs near the breakpoint.

Drug (%S, I, R)	EA	CA	VME	ME	miE	Adjusted miE*
ATM (57, 11, 32)	77%	87%	1 (2.9%)	2 (3.3%)	11 (10%)	5 (4.8%)
FEP (50, 20, 30)	72%	64%	0	7 (13%)	31 (29%)	11 (10.5%)
CAZ (68, 10, 22)	82%	90%	1 (4.2%)	0	9 (8.6%)	3 (2.9%)
CZA (90, -, 10)	78%	93%	2 (18%)* 0* (0.0%)	5 (5.3%)* 2* (2.1%)	NA	NA
CT (92, 2, 6)	86%	93%	0	1 (1%)	6 (5.7%)	1 (1.0%)
CIP (27, 14, 59)	79%	85%	0	0	16 (15%)	5 (4.8%)
LEV (24, 13, 63)	63%	83%	0	0	18 (17%)	8 (7.6%)
MEM (58, 6, 36)	86%	91%	0	2 (3.3%)	7 (7%)	3 (2.9%)
TZP (67, 13, 20)	77%	85%	0	2 (2.9%)	14 (13%)	11 (10.5%)
TOB (63, 13, 24)	82%	81%	0	1 (1.5%)	19 (18%)	6 (5.7%)

*Adjusted errors (excluding within EA errors) applied to miE and VME/ME for drugs without “Intermediate” category

Disclosures. Joseph L. Kuti, PharmD, Allergan (Speaker’s Bureau) bioMérieux (Research Grant or Support, Other Financial or Material Support, Speaker Honorarium) Melinta (Research Grant or Support) Merck & Co., Inc. (Research Grant or Support) Paratek (Speaker’s Bureau) Summit (Other Financial or Material Support, Research funding (clinical trials)) David P. Nicolau, PharmD, Cepheid (Other Financial or Material Support, Consultant, speaker bureau member or has received research support) Merck & Co., Inc. (Consultant, Grant/Research Support, Speaker’s Bureau) Wockhardt (Grant/Research Support)

14. Outcomes from the AHRQ Safety Program for Improving Antibiotic Use Across 439 Long-term Care Facilities

Morgan Katz, MD, MHS¹; Theresa A. Rowe, MD²; Sara E Cosgrove, MD, MS³; Pranita D. Tamma, MD, MHS⁴; Melissa A. Miller, MD, MS⁵; Prashila Dullabh, MD⁶; Kathleen Speck, MPH⁷; Roy Ahn, MPH, ScD⁸; Yue Gao, MPH⁹; Erik Scherpf, Ph.D.⁶; Robin Jump, MD, PhD³; Robin Jump, MD, PhD³; Johns Hopkins University, pikesville, Maryland; ²Northwestern University Feinberg School of Medicine, Chicago, Illinois; ³Johns Hopkins University of Medicine, Baltimore, Maryland; ⁴Johns Hopkins University School of Medicine, Baltimore, Maryland; ⁵Agency for Healthcare Research and Quality, Rockville, Maryland; ⁶NORC at the University of Chicago, Bethesda, Maryland; ⁷Johns Hopkins, Baltimore, Maryland; ⁸NORC, Chicago, Illinois; ⁹VA Northeast Ohio Healthcare System, Cleveland, Ohio

Session: O-4. Antimicrobial Stewardship in Special Populations/Non-Acute Care

Background. Implementing effective antibiotic stewardship programs (ASPs) in long-term care (LTC) settings is challenging. We present the results of an intervention intended to change the culture of antibiotic prescribing in 439 United States LTC facilities (LTCF).

Methods. The LTC Safety Program assisted LTCFs with establishing and implementing ASPs from 12/2018 to 11/2019. Through webinars held 1–2 times per month and other educational content, the Safety Program emphasized 1) the science of safety to improve teamwork and identify antibiotic-associated harm and 2) clinical best practices in making antibiotic treatment decisions. Content was organized using the Four Moments of Antibiotic Decision Making Framework (Figure 1). All staff (e.g., physicians, nurses, nurse assistants) were encouraged to participate. LTCFs submitted monthly antibiotic days of therapy (DOT), numbers of new antibiotic starts, urine cultures (UCX) ordered, *Clostridioides difficile* LabID events, and census data. Generalized linear mixed effects models were used to calculate pre-post intervention changes at bi-monthly intervals for antibiotic DOT, antibiotic starts and UCX, each per 1,000 resident-days (RD), and *C. difficile* LabID events per 10,000 RD, comparing the beginning (1/2019 and 2/2019) and end (11/2019 and 12/2019) of the Safety Program.